Resources
12 Results (showing 1 - 10)
Results sorted by updated date (oldest first)
Results sorted by updated date (oldest first)
Posted 3/21/2023 (updated 3/27/2024)
Training materials A Stimulating Talk
Posted 5/16/2023 (updated 3/27/2024)
Xylazine, a veterinary tranquilizer not approved for human use, has been increasingly identified in parts of the U.S. illicit drug supply.
Posted 7/14/2023 (updated 3/28/2024)
The Centers for Disease Control and Prevention released data showing a significant increase – 276 percent in 21 jurisdictions from 2019 to 2022 – in overdose deaths involving Xylazine, a nonopioid sedative that’s been detected in illicitly manufactured fentanyl drug products.
Posted 7/26/2023 (updated 3/28/2024)
This session discussed the barriers typically encountered and workarounds such as money, staff, and location. We encouraged participants to bring successes, near successes, and non-successes in expanding access over the last 3 years.
Posted 7/26/2023 (updated 3/28/2024)
This presentation provided an overview of the (1) current U.S. prevalence of opioid abuse and OUD and their societal consequences, (2) impacts of the opioid epidemic on rural geographic areas and populations, (3) recent emergence of synthetic opioids (e.g., fentanyl) and xylazine in the U.S. drug supply, and (4) most empirically supported treatment for patients with OUD.
Posted 7/26/2023 (updated 3/28/2024)
Effective prevention includes Design, Development, and Delivery. This session addressed the critical need to follow the science, what the science is, and how the Randolph County Caring Community (RCCC) has Designed, Developed, and Delivered an evidence-based prevention system in their area. Participants learned how the PROSPER (PROmoting School-community-university Partnerships to Enhance Resilience) model has brought additional partners to its consortium, leading to the use of tested and effective prevention programs.
Posted 11/19/2019 (updated 3/28/2024)
This guidance document is intended to support the development of comprehensive prevention. Work Plans that are based on local data and designed to achieve measurable outcomes.
Posted 5/27/2020 (updated 3/28/2024)
Materials from the Strategies for Engaging Your Community During the Pandemic webinar held on May 19, 2020 are below.
Posted 9/4/2020 (updated 3/29/2024)
The analysis examined syndromic surveillance data from 2018–2019 in 29 states for suspected nonfatal drug and polydrug overdoses treated in emergency departments.
Posted 8/11/2020 (updated 4/2/2024)
Non-fatal opioid overdose (NFOO) is a significant cause of opioid-related morbidity in the United States. As the number of NFOOs continues to grow, it is important to understand the short- and long-term consequences of NFOO. This report examines the existing literature on the acute and chronic health and functional outcomes of individuals who experience NFOO, and also identifies differences in outcomes for NFOOs involving illicitly-manufactured fentanyl.